New York (United States), Sept. 20, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited ("Lifezone Metals" or the "Company") (NYSE: LZM), a modern metals company creating value across the battery metals supply chain [...] Read more »
[INVNT GROUP]™ achieves record global growth, accelerating history-making brand campaigns, strategic partnerships, and humanitarian work.
New York, NY, May 11, 2023 (GLOBE NEWSWIRE) — [INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT and leading agency portfolio of complementary brand storytelling disciplines, continues its explosive growth trajectory and worldwide [...] Read more »
Cellebrite Announces First-Quarter 2023 Results
Revenue of $71.2 million, 14% year–over–year increase due primarily to
27% growth in subscription revenue;
ARR of $261.3 million, up 30% [...] Read more »
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Cellebrite Announces Fourth Quarter 2022 Results
ARR of $249 million, up 33% year–over–year
Fourth–quarter revenue of $74.0 million, [...] Read more »
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Risk of symptomatic COVID–19 was reduced by 71% compared to placebo in pre–exposure prophylaxis and 75% compared to placebo in post–exposure prophylaxis
Risk of [...] Read more »
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID–19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second [...] Read more »